2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases

Annals of the Rheumatic Diseases

Volumn 79, Issue 1, 2020, Pages 39-52

  Furer, Victoria ^a,b   Rondaan, Christien ^c   Heijstek, Marloes W ^d   Agmon Levin, Nancy ^b,e   Van Assen, Sander ^f   Bijl, Marc ^g   Breedveld, Ferry C ^h   D'amelio, Raffaele ⁱ   Dougados, Maxime ^j   Kapetanovic, Meliha Crnkic ^k   Van Laar, Jacob M ^d   De Thurah, A ^l   Landewé, Robert B M ^m,n   Molto, Anna ^j   Müller Ladner, Ulf ^o   Schreiber, Karen ^p,q   Smolar, Leo ^r   Walker, Jim ^s   Warnatz, Klaus ^t   Wulffraat, Nico M ^u   Elkayam, Ori ^a,b   more..

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e SHEBA MEDICAL CENTER   (Israel)

^f Location Bethesda Hoogeveen   (Netherlands)

^g MARTINI HOSPITAL   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j Institut Cochin   (France)

^k LUND UNIVERSITY   (Sweden)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ Zuyderland Medical Centre   (Netherlands)

^o JUSTUS LIEBIG UNIVERSITY   (Germany)

^p GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^q King Christian the Xth Hospital   (Denmark)

^r Patient Research Partner   (Israel)

^s PMR GCA North East   (United Kingdom)

^t UNIVERSITY OF FREIBURG   (Germany)

^u UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

autoimmune diseases; infections; vaccination

Indexed keywords

ADALIMUMAB; ANAKINRA; AZATHIOPRINE; BCG VACCINE; BELIMUMAB; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; ETANERCEPT; GLUCOCORTICOID; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLUENZA VACCINE; IXEKIZUMAB; LEFLUNOMIDE; MEASLES VACCINE; METHOTREXATE; PNEUMOCOCCUS VACCINE; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; TACROLIMUS; TETANUS TOXOID; TOCILIZUMAB; UNINDEXED DRUG; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; ANTIRHEUMATIC AGENT; LIVE VACCINE; VACCINE;

ANCA ASSOCIATED VASCULITIS; ARTICLE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; INFLUENZA VACCINATION; MILIARY TUBERCULOSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHARED DECISION MAKING; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VACCINATION; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CONSENSUS DEVELOPMENT; FAMILY SIZE; HEPATITIS A; HEPATITIS B; HERPES ZOSTER; INFLUENZA; PAPILLOMAVIRUS INFECTION; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; TETANUS; VIRUS INFECTION;

ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; FAMILY CHARACTERISTICS; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS B; HEPATITIS B VACCINES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RHEUMATIC DISEASES; TETANUS; TETANUS TOXOID; VACCINES; VACCINES, ATTENUATED; VIRUS DISEASES;

EID: 85070953188     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-215882     Document Type: Article

References (209)

1. Weaver A, Troum O, Hooper M, et al. Rheumatoid arthritis disease activity and disability affect the risk of serious infection events in radius 1. J Rheumatol 2013;40:1275-81.
2. Danza A, Ruiz-Irastorza G. Infection risk in systemic lupus erythematosus patients: Susceptibility factors and preventive strategies. Lupus 2013;22:1286-94.
3. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 2013;52:53-61.
4. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785-91.
5. Galicia-Hernández G, Parra-Salcedo F, Ugarte-Martínez P, et al. Sustained moderate-to- high disease activity and higher Charlson score are predictors of incidental serious infection events in RA patients treated with conventional disease-modifying anti-rheumatic drugs: A cohort study in the treat-to- target era. Clin Exp Rheumatol 2016;34:261-9.
6. Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: A systematic literature review Informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1101-36.
7. Germano V, Cattaruzza MS, Osborn J, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-á antagonists. J Transl Med 2014;12:77.
8. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
9. Gossec L, Smolen JS, Ramiro S, et al. European League against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499-510.
10. van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978-91.
11. Fernandez-Martinez S, Cortes X, Borrás-Blasco J, et al. Effectiveness of a systematic vaccination program in patients with autoimmune inflammatory disease treated with anti-TNF alpha drugs. Expert Opin Biol Ther 2016;16:1317-22.
12. Costello R, Winthrop KL, Pye SR, et al. Influenza and pneumococcal vaccination uptake in patients with rheumatoid arthritis treated with immunosuppressive therapy in the UK: A retrospective cohort study using data from the clinical practice research Datalink. PLoS One 2016;11:e0153848.
13. Sandler DS, Ruderman EM, Brown T, et al. Understanding vaccination rates and attitudes among patients with rheumatoid arthritis. Am J Manag Care 2016;22:161-7.
14. McCarthy EM, de Barra E, Bergin C, et al. Influenza and pneumococcal vaccination and varicella status in inflammatory arthritis patients. Ir Med J 2011;104:208-11.
15. Nguyen M, Lindegaard H, Hendricks O, et al. Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax-RA). Scand J Rheumatol 2017;46:446-53.
16. Brocq O, Acquacalda E, Berthier F, et al. Influenza and pneumococcal vaccine coverage in 584 patients taking biological therapy for chronic inflammatory joint: A retrospective study. Joint Bone Spine 2016;83:155-9.
17. Hmamouchi I, Winthrop K, Launay O, et al. Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: Data from the International COMORA cohort. Vaccine 2015;33:1446-52.
18. Morin M-P, Quach C, Fortin E, et al. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology 2012;51:2046-50.
19. Curtis JR, Xie F, Chen L, et al. Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. Arthritis Care Res 2012;64:1480-9.10.1002/acr.21805
20. Ng B, McBain L, Grainger R. Rheumatologists fail to advise people with RA to get immunised, which matters if you are under 65: An audit in a new Zealand rheumatology service. N Z Med J 2016;129:72-8.
21. Lawson EF, Trupin L, Yelin EH, et al. Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. Semin Arthritis Rheum 2015;44:666-71.
22. van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis 2015;74:8-13.
23. Oxford centre for evidence-based medicine - levels of evidence. The Oxford 2009. level of evidence updated in 2012; 2012. https://wwwcebmnet/2009/06/oxfordcentre- evidence-based-medicine-levels-evidence-march-2009/
24. Brouwers MC, Kho ME, Browman GP, et al. Agree II: Advancing Guideline development, reporting and evaluation in health care. Can Med Assoc J 2010;182:E839-E842.10.1503/cmaj.090449
25. van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
26. Loubet P, Kernéis S, Groh M, et al. Attitude, knowledge and factors associated with influenza and pneumococcal vaccine uptake in a large cohort of patients with secondary immune deficiency. Vaccine 2015;33:3703-8.
27. Subesinghe S, Rutherford AI, Ibrahim F, et al. A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK. BMC Musculoskelet Disord 2016;17:322.
28. Milanovic M, Stojanovich L, Djokovic A, et al. Influenza vaccination in autoimmune rheumatic disease patients. Tohoku J Exp Med 2013;229:29-34.
29. Holvast A, van Assen S, de Haan A, et al. Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: An open, prospective, controlled study. Rheumatology 2009;48:1294-9.
30. Mok CC, Ho LY, Fong LS, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: A case-control study. Ann Rheum Dis 2013;72:659-64.
31. Holvast A, de Haan A, van Assen S, et al. Cell-Mediated immune responses to influenza vaccination in Wegener's granulomatosis. Ann Rheum Dis 2010;69:924-7.
32. David Morgan M, Richter A, Al-Ali S, et al. Association of low B cell count and IgG levels with infection, and poor vaccine response with all-cause mortality in an immunosuppressed vasculitis population. Arthritis Care Res 2016;68:853-60.10.1002/acr.22757
33. Liao Z, Tang H, Xu X, et al. Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: A meta-analysis. PLoS One 2016;11:e0147856.
34. Campos LMA, Silva CA, Aikawa NE, et al. High disease activity: An independent factor for reduced immunogenicity of the pandemic influenza A vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res 2013;65:1121-7.10.1002/acr.21948
35. Ribeiro ACM, Guedes LKN, Moraes JCB, et al. Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: Implications for clinical practice. Ann Rheum Dis 2011;70:2144-7.
36. Bingham CO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74.
37. Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor á, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res 2014;66:1016-26.10.1002/acr.22246
38. Adler S, Krivine A, Weix J, et al. Protective effect of A/H1N1 vaccination in immune-mediated disease-A prospectively controlled vaccination study. Rheumatology 2012;51:695-700.10.1093/rheumatology/ker389
39. Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013;33:388-96.
40. Gabay C, Bel M, Combescure C, et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study. Arthritis Rheum 2011;63:1486-96.
41. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81.
42. Kapetanovic MC, Kristensen L-E, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther 2014;16.
43. Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643-8.
44. Westra J, van Assen S, Wilting KR, et al. Rituximab impairs immunoglobulin (Ig) M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 2014;178:40-7.
45. Nguyen MTT, Lindegaard H, Hendricks O, et al. Initial serological response after prime-boost pneumococcal vaccination in rheumatoid arthritis patients: Results of a randomized controlled trial. J Rheumatol 2017;44:1794-803.
46. Rehnberg M, Brisslert M, Amu S, et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther 2010;12.
47. Crnkic Kapetanovic M, Saxne T, Jönsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther 2013;15.10.1186/ar4358
48. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1724-31.
49. Heijstek MW, van Gageldonk PGM, Berbers GAM, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: A retrospective cross-sectional study. Ann Rheum Dis 2012;71:948-54.
50. Miyamoto M, Ono E, Barbosa C, et al. Vaccine antibodies and T- And B-cell interaction in juvenile systemic lupus erythematosus. Lupus 2011;20:736-44.
51. Borte S, Liebert UG, Borte M, et al. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology 2009;48:144-8.
52. Heijstek MW, Kamphuis S, Armbrust W, et al. Effects of the live attenuated measles-mumps- rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: A randomized trial. JAMA 2013;309:2449-56.
53. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012;308:43-9.
54. Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: A pilot study of immunogenicity. J Rheumatol 2013;40:1875-80.
55. Dirven L, Huizinga TWJ, Allaart CF. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis. Scand J Rheumatol 2012;41:359-65.
56. Blumentals WA, Arreglado A, Napalkov P, et al. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: A retrospective cohort study. BMC Musculoskelet Disord 2012;13:158.
57. Carvalho LM, de Paula FE, Silvestre RVD, et al. Prospective surveillance study of acute respiratory infections, influenza-like illness and seasonal influenza vaccine in a cohort of juvenile idiopathic arthritis patients. Pediatr Rheumatol Online J 2013;11.
58. Chen C-M, Chen H-J, Chen W-S, et al. Clinical effectiveness of influenza vaccination in patients with rheumatoid arthritis. Int J Rheum Dis 2018;21:1246-53.
59. Kostianovsky A, Charles P, Alves J-F, et al. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: A prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012;30(1 Suppl 70):S83-9.
60. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-76.
61. Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations. Clin Infect Dis 2002;35:370-7.
62. Chang C-C, Chang Y-S, Chen W-S, et al. Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: A nationwide cohort study. Sci Rep 2016;6:37817.
63. Kobashigawa T, Nakajima A, Taniguchi A, et al. Vaccination against seasonal influenza is effective in Japanese patients with rheumatoid arthritis enrolled in a large observational cohort. Scand J Rheumatol 2013;42:445-50.
64. Kivitz AJ, Schechtman J, Texter M, et al. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: Results from a single-blind randomized phase IV trial. J Rheumatol 2014;41:648-57.
65. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-9.
66. Denman EJ, Denman AM, Greenwood BM, et al. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis 1970;29:220-31.
67. Kapetanovic MC, Saxne T, Nilsson J-A, et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology 2007;46:608-11.
68. Kubota T, Nii T, Nanki T, et al. Anti-Tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2007;17:531-3.
69. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
70. Gelinck LBS, van der Bijl AE, Beyer WEP, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67:713-6.
71. Herron A, Dettleff G, Hixon B, et al. Influenza vaccination in patients with rheumatic diseases. safety and efficacy. JAMA 1979;242:53-6.
72. Turner-Stokes L, Cambridge G, Corcoran T, et al. In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases. Ann Rheum Dis 1988;47:532-5.
73. Del Porto F, Lagana B, Biselli R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. safety and immunogenicity. Vaccine 2006;24:3217-23.
74. Elkayam O, Bashkin A, Mandelboim M, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010;39:442-7.
75. Williams GW, Steinberg AD, Reinertsen JL, et al. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med 1978;88:729-34.
76. Ristow SC, Douglas RG, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med 1978;88:786-9.
77. Brodman R, Gilfillan R, Glass D, et al. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med 1978;88:735-40.
78. Louie JS, Nies KM, Shoji KT, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med 1978;88:790-2.
79. Winthrop KL, Silverfield J, Racewicz A, et al. The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis. Ann Rheum Dis 2016;75:687-95.
80. Pons VG, Reinertsen JL, Steinberg AD, et al. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol 1979;4:15-23.
81. Abu-Shakra M, Press J, Varsano N, et al. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol 2002;29:2555-7.
82. Mercado U, Acosta H, Avendano L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin 2004;56:16-20.
83. Holvast A, Huckriede A, Wilschut J, et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease. Ann Rheum Dis 2006;65:913-8.
84. Holvast A, Stegeman CA, Benne CA, et al. Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009;68:873-8.
85. Chalmers A, Scheifele D, Patterson C, et al. Immunization of patients with rheumatoid arthritis against influenza: A study of vaccine safety and immunogenicity. J Rheumatol 1994;21:1203-6.
86. Zycinska K, Romanowska M, Nowak I, et al. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol 2007;58 Suppl 5:819-28.
87. Tsuru T, Terao K, Murakami M, et al. Immune response to influenza vaccine and pneumococcal polysaccharide vaccine under IL-6 signal inhibition therapy with tocilizumab. Mod Rheumatol 2014;24:511-6.
88. Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (rA). Clin Dev Immunol 2006;13:373-5.
89. Milanetti F, Germano V, Nisini R, et al. Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals. Clin Exp Immunol 2014;177:287-94.10.1111/cei.12292
90. Wallin L, Quintilio W, Locatelli F, et al. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009;34:498-502.
91. Wiesik-Szewczyk E, Romanowska M, Mielnik P, et al. Anti-Influenza vaccination in systemic lupus erythematosus patients: An analysis of specific humoral response and vaccination safety. Clin Rheumatol 2010;29:605-13.
92. Crowe SR, Merrill JT, Vista ES, et al. Influenza vaccination responses in human systemic lupus erythematosus: Impact of clinical and demographic features. Arthritis Rheum 2011;63:2396-406.
93. Launay O, Paul S, Servettaz A, et al. Control of humoral immunity and auto-immunity by the CXCR4/CXCL12 axis in lupus patients following influenza vaccine. Vaccine 2013;31:3492-501.
94. Litinsky I, Balbir A, Zisman D, et al. Vaccination against influenza in patients with systemic sclerosis. Clin Exp Rheumatol 2012;30(2 Suppl 71):S7-11.
95. Polachek A, Korobko U, Mader-Balakirski N, et al. Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis. Clin Exp Rheumatol 2015;33:181-6.
96. Caso F, Ramonda R, Del Puente A, et al. Influenza vaccine with adjuvant on disease activity in psoriatic arthritis patients under anti-TNF- Á therapy. Clin Exp Rheumatol 2016;34:507-12.
97. Nii T, Kubota T, Nanki T, et al. Reevaluation of antibody titers 1 year after influenza vaccination in patients with rheumatoid arthritis receiving TNF blockers. Mod Rheumatol 2009;19:216-8.
98. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNFalpha blockers: Safety and immunogenicity. Clin Immunol 2010;134:113-20.
99. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-41.
100. Gelinck LBS, Teng YKO, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis 2007;66:1402-3.
101. Park JK, Lee MA, Lee EY, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis 2017;76:1559-65.
102. Park JK, Lee YJ, Shin K, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial. Ann Rheum Dis 2018;388:annrheumdis-2018-213222-904.10.1136/annrheumdis-2018-213222
103. Vista ES, Crowe SR, Thompson LF, et al. Influenza vaccination can induce new-onset anticardiolipins but not â2-glycoprotein- I antibodies among patients with systemic lupus erythematosus. Lupus 2012;21:168-74.
104. Setti M, Fenoglio D, Ansaldi F, et al. Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27:3367-72.
105. Saad CGS, Borba EF, Aikawa NE, et al. Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068-73.
106. Elkayam O, Amir S, Mendelson E, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res 2011;63:1062-7.10.1002/acr.20465 107 França ILA, Ribeiro ACM, Aikawa NE, et al. Tnf blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology 2012;51:2091-8.
107. Iwamoto M, Homma S, Onishi S, et al. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int 2012;32:3691-4.
108. Miraglia JL, Abdala E, Hoff PM, et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS One 2011;6:e27214.10.1371/journal. pone. 0027214
109. Kapetanovic MC. Further evidence for influenza and pneumococcal vaccination in patients treated with disease modifying antirheumatic drugs and anti-tumor necrosis factor agents. J Rheumatol 2014;41:626-8.
110. Lu C-C, Wang Y-C, Lai J-H, et al. A/H1N1 influenza vaccination in patients with systemic lupus erythematosus: Safety and immunity. Vaccine 2011;29:444-50.
111. Aikawa NE, Campos LMA, Silva CA, et al. Glucocorticoid: Major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol 2012;39:167-73.
112. Borba EF, Saad CGS, Pasoto SG, et al. Influenza A/H1N1 vaccination of patients with SLE: Can antimalarial drugs restore diminished response under immunosuppressive therapy? Rheumatology 2012;51:1061-9.
113. Shinjo SK, de Moraes JCB, Levy-Neto M, et al. Pandemic unadjuvanted influenza A (H1N1) vaccine in dermatomyositis and polymyositis: Immunogenicity independent of therapy and NO harmful effect in disease. Vaccine 2012;31:202-6.
114. Miossi R, Fuller R, Moraes JCB, et al. Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: Effect of disease and therapy. Clinics 2013;68:129-33.
115. Pasoto SG, Ribeiro AC, Viana VST, et al. Short and long-term effects of pandemic unadjuvanted influenza A(H1N1)pdm09 vaccine on clinical manifestations and autoantibody profile in primary Sjögren's syndrome. Vaccine 2013;31:1793-8.
116. Ribeiro AC, Laurindo IM, Guedes LK, et al. Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care Res 2013;65:476-80.10.1002/acr.21838
117. Mathian A, Devilliers H, Krivine A, et al. Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis Rheum 2011;63:3502-11.
118. Aikawa NE, Campos LMA, Goldenstein-Schainberg C, et al. Effective seroconversion and safety following the pandemic influenza vaccination (anti-H1N1) in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2013;42:34-40.10.3109/03009742.2012.709272
119. Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990-7.10.1002/acr.22281
120. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1.
121. Luijten RKMAC, Cuppen BVJ, Bijlsma JWJ, et al. Serious infections in systemic lupus erythematosus with a focus on pneumococcal infections. Lupus 2014;23:1512-6.
122. Izumi Y, Akazawa M, Akeda Y, et al. The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: A double-blinded, randomized, placebo-controlled trial. Arthritis Res Ther 2017;19.10.1186/s13075-016-1207-7
123. Coulson E, Saravanan V, Hamilton J, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. Ann Rheum Dis 2011;70:1289-91.
124. Migita K, Akeda Y, Akazawa M, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. Arthritis Res Ther 2015;17.10.1186/s13075-015-0662-x
125. Migita K, Akeda Y, Akazawa M, et al. Opsonic and antibody responses to pneumococcal polysaccharide in rheumatoid arthritis patients receiving golimumab plus methotrexate. Medicine 2015;94:e2184.
126. Mori S, Ueki Y, Akeda Y, et al. Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy. Ann Rheum Dis 2013;72:1362-6.
127. Bingham CO, Rizzo W, Kivitz A, et al. Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: Results of a randomised controlled trial (VISARA). Ann Rheum Dis 2015;74:818-22.
128. Migita K, Akeda Y, Akazawa M, et al. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients. Arthritis Res Ther 2015;17.10.1186/s13075-015-0863-3
129. Rezende RPV, Ribeiro FM, Albuquerque EMN, et al. Immunogenicity of pneumococcal polysaccharide vaccine in adult systemic lupus erythematosus patients undergoing immunosuppressive treatment. Lupus 2016;25:1254-9.
130. Alyasin S, Adab M, Hosseinpour A, et al. Immunogenicity of 23-valent pneumococcal vaccine in children with systemic lupus erythematosus. Iran J Immunol 2016;13:204-19.
131. Chatham W, Chadha A, Fettiplace J, et al. A randomized, open-label study to investigate the effect of belimumab on pneumococcal vaccination in patients with active, autoantibody-positive systemic lupus erythematosus. Lupus 2017;26:1483-90.
132. Fischer L, Gerstel PF, Poncet A, et al. Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases - A longitudinal study. Arthritis Res Ther 2015;17.10.1186/s13075-015-0663- 910.1186/s13075-015-0663-9
133. Broyde A, Arad U, Madar-Balakirski N, et al. Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases. J Rheumatol 2016;43:267-72.10.3899/jrheum.150397
134. Rákóczi Eva, Perge B, Végh E, et al. Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. Joint Bone Spine 2016;83:675-9.
135. Kapetanovic MC, Nagel J, Nordström I, et al. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine. Vaccine 2017;35:903-8.
136. Nagel J, Saxne T, Geborek P, et al. Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccine. Lupus 2017;26:1072-81.10.1177/0961203317695465
137. Nived P, Nagel J, Saxne T, et al. Immune response to pneumococcal conjugate vaccine in patients with systemic vasculitis receiving standard of care therapy. Vaccine 2017;35:3639-46.
138. Walker UA, Hoffman HM, Williams R, et al. Brief Report: Severe Inflammation Following Vaccination Against Streptococcus pneumoniae in Patients With Cryopyrin-Associated Periodic Syndromes. Arthritis Rheumatol 2016;68:516-20.
139. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. Vaccine 2014;32:2364-74.
140. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine 2013;31:3594-602.
141. Lesprit P, Pédrono G, Molina J-M, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007;21:2425-34.
142. Centers for Disease Control and Prevention (CDC). Licensure of 13-valent pneumococcal conjugate vaccine for adults aged 50 years and older. MMWR Morb Mortal Wkly Rep 2012;61:394-5.
143. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64:944-7.
144. Esposito S, Bonanni P, Maggi S, et al. Recommended immunization schedules for adults: Clinical practice guidelines by the ESCMID vaccine Study Group (EVASG), European geriatric medicine Society (EUGMS) and the world association for infectious diseases and immunological disorders (WAidid). Hum Vaccin Immunother 2016;12:1-18.
145. Devey ME, Bleasdale K, Isenberg DA. Antibody affinity and IgG subclass of responses to tetanus toxoid in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1987;68:562-9.
146. Battafarano DF, Battafarano NJ, Larsen L, et al. Antigen-Specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998;41:1828-34.
147. Kashef S, Ghazizadeh F, Derakhshan A, et al. Antigen-Specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol 2008;5:181-4.
148. Bingham CO, Winthrop KL, Yang L, et al. Baff inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis. Arthritis Res Ther 2015;17.10.1186/s13075-015-0867-z
149. Chatham WW, Wallace DJ, Stohl W, et al. Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial. J Rheumatol 2012;39:1632-40.
150. Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis a vaccine for immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Travel Med Infect Dis 2014;12:134-42.10.1016/j. tmaid.2014.01.005
151. van den Bijllaardt W, Siers HM, Timmerman-Kok C, et al. Seroprotection after hepatitis A vaccination in patients with Drug-Induced immunosuppression. J Travel Med 2013;20:278-82.10.1111/jtm.12050
152. Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis 2002;61:623-5.
153. Erkek E, Ayaslioglu E, Erkek AB, et al. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol 2005;20:1508-11.
154. Kuruma KAM, Borba EF, Lopes MH, et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus 2007;16:350-4.
155. Aytac MB, Kasapcopur O, Aslan M, et al. Hepatitis B vaccination in juvenile systemic lupus erythematosus. Clin Exp Rheumatol 2011;29:882-6.
156. Intongkam S, Samakarnthai P, Pakchotanon R, et al. Efficacy and safety of hepatitis B vaccination in rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs and/or biologics therapy. J Clin Rheumatol 2018. doi:10.1097/RHU.0000000000000877. [Epub ahead of print: 27 Jul 2018].
157. Haykir Solay A, Eser F. High dose hepatitis B vaccine is not effective in patients using immunomodulatory drugs: A pilot study. Hum Vaccin Immunother 2019;15:1177-82.
158. https://www. cdc. gov/vaccines/pubs/pinkbook/downloads/hepb. pdf
159. Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: Implications for vaccination. Arthritis Rheumatol 2016;68:2328-37.
160. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84.
161. Schmader KE, Levin MJ, Gnann JW, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8.
162. Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:1336-44.
163. Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: A randomized phase II trial. Arthritis Rheumatol 2017;69:1969-77.
164. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087-96.
165. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med 2016;375:1019-32.
166. WHO. WHO position paper on vaccines and vaccination against yellow fever; 2013.
167. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res 2010;62:896-8.10.1002/acr.20045
168. Oliveira ACV, Mota LMH, Santos-Neto LL, et al. Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever. Arthritis Rheumatol 2015;67:582-3.
169. Kernéis S, Launay O, Ancelle T, et al. Safety and immunogenicity of yellow fever 17D vaccine in adults receiving systemic corticosteroid therapy: An observational cohort study. Arthritis Care Res 2013;65:1522-8.10.1002/acr.22021
170. Staples JE, Gershman M, Fischer M, et al. Yellow fever vaccine: Recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Recomm Rep 2010;59:1-27.
171. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010;19:1485-91.10.1177/0961203310372952
172. Lee Y-H, Choe J-Y, Park S-H, et al. Prevalence of human papilloma virus infections and cervical cytological abnormalities among Korean women with systemic lupus erythematosus. J Korean Med Sci 2010;25:1431-7.
173. Lyrio LDC, Grassi MFR, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 2013;33:335-40.
174. Mendoza-Pinto C, García-Carrasco M, Vallejo-Ruiz V, et al. Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women. Lupus 2017;26:944-51.
175. Méndez-Martínez S, García-Carrasco M, Jiménez-Herrera EA, et al. Factors of the epidemiological triad that influence the persistence of human papilloma virus infection in women with systemic lupus erythematosus. Lupus 2018;27:1542-6.
176. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013;11.
177. Dhar JP, Essenmacher L, Dhar R, et al. The safety and immunogenicity of quadrivalent HPV (qHPV) vaccine in systemic lupus erythematosus. Vaccine 2017;35:2642-6.10.1016/j.vaccine.2017.04.001
178. Mok CC, Ho LY, To CH. Long-Term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus. Vaccine 2018;36:3301-7.
179. Akioka S. Bivalent HPV vaccine safety depending on subtypes of juvenile idiopathic arthritis. Ann Rheum Dis 2014;73:e75.
180. Geier DA, Geier MR. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events. Clin Rheumatol 2015;34:1225-31.
181. Holt HD, Hinkle DM, Falk NS, et al. Human papilloma virus vaccine associated uveitis. Curr Drug Saf 2014;9:65-8.
182. Hotta O, Tanaka A, Torigoe A, et al. Involvement of chronic epipharyngitis in autoimmune (auto-inflammatory) syndrome induced by adjuvants (Asia). Immunol Res 2017;65:66-71.
183. Ito H, Noda K, Hirai K, et al. A case of systemic lupus erythematosus (SLE) following human papillomavirus (HPV) vaccination. Jpn. J. clin. Immun 2016;39:145-9.
184. Soldevilla HF, Briones SFR, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21:158-61.
185. Grönlund O, Herweijer E, Sundström K, et al. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: A cohort study. J Intern Med 2016;280:618-26.
186. Arnheim-Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: Cohort study. BMJ 2013;347:f5906.
187. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271:193-203.
188. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014;58:309-18.
189. Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Rev Vaccines 2016;15:239-56.
190. Mariette X, Förger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: Results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018;77:228-33.
191. Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine 2016;83:341-3.
192. Julsgaard M, Christensen LA, Gibson PR, et al. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016;151:110-9.
193. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013;11:286-92. quiz e24.
194. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011;33:1053-8.
195. Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: Drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009;68:1793-4.
196. Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010;49:2225-7.
197. Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica 2006;91:1426-7.
198. Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world Congress of gastroenterology on biological therapy for IBD with the European Crohn's and colitis organisation: Pregnancy and pediatrics. Am J Gastroenterol 2011;106:214-23. quiz 24.
199. Cheent K, Nolan J, Shariq S, et al. Case report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010;4:603-5.
200. Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol 2013;108:1426-38.
201. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75:795-810.
202. Crowson CS, Hoganson DD, Fitz-Gibbon PD, et al. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2847-55.
203. Zink A, Manger B, Kaufmann J, et al. Evaluation of the rabbit risk score for serious infections. Ann Rheum Dis 2014;73:1673-6.
204. Chen H-H, Chen Y-M, Chen T-J, et al. Risk of herpes zoster in patients with systemic lupus erythematosus: A three-year follow-up study using a nationwide population-based cohort. Clinics 2011;66:1177-82.
205. Gormezano NWS, Silva CA, Otsuzi CI, et al. Higher prevalence and distinct features of herpes zoster infection in children than adults with systemic lupus erythematosus. Pediatr Infect Dis J 2015;34:905-7.
206. Wu S-A, Yeh K-W, Yao T-C, et al. Association of herpes zoster infection with clinical characteristics and MBL2 gene polymorphisms in Chinese children with systemic lupus erythematosus. Pediatr Infect Dis J 2011;30:656-60.
207. Ferreira JCOA, Marques HH, Ferriani MPL, et al. Herpes zoster infection in childhood-onset systemic lupus erythematosus patients: A large multicenter study. Lupus 2016;25:754-9.
208. Baker B, Eça Guimaraes L, Tomljenovic L, et al. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf 2015;14:1387-94.
209. Segal Y, Calabro M, Kanduc D, et al. Human papilloma virus and lupus: The virus, the vaccine and the disease. Curr Opin Rheumatol 2017;29:331-42.